论文部分内容阅读
[目的]观察金双歧对肝硬化自发性细菌性腹膜炎(SBP)患者肠黏膜屏障功能的保护作用,以及临床疗效分析。[方法]收集2013年1月~2015年9月我院感染科收治的肝硬化伴发SBP患者92例,患者使用数字法随机分为常规治疗对照组和金双歧辅助治疗观察组,每组46例。比较2组治疗前后血清二胺氧化酶(DAO)、D-乳酸(D-Lac)、内毒素(ET)、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)表达的改变,以及临床疗效。[结果]2组治疗前DAO、D-Lac、ET、IL-6和TNF-α表达差异无统计学意义(P>0.05),治疗后2组DAO、D-Lac、ET、IL-6和TNF-α均显著减低(P<0.01),但观察组对DAO、D-Lac、ET、IL-6和TNF-α的减低作用显著优于对照组(P<0.05)。观察组的临床治疗有效率为89.13%(41/46),显著高于对照组的71.74%(33/46)(P<0.05)。[结论]金双歧辅助治疗肝硬化SBP,可以保护肠黏膜,抑制炎症反应,临床疗效显著,值得临床推广使用。
[Objective] To observe the protective effect of Jinshuangqi on intestinal mucosal barrier function in patients with cirrhosis spontaneous bacterial peritonitis (SBP) and its clinical efficacy. [Methods] Ninety-two patients with cirrhosis and SBP were collected from January 2013 to September 2015 in our hospital. The patients were randomly divided into routine treatment group and Jinshuqi adjuvant treatment observation group with 46 cases in each group . The serum levels of DAO, D-Lac, ET, IL-6 and TNF-α were compared between the two groups before and after treatment Change, and clinical efficacy. [Results] There were no significant differences in the expression of DAO, D-Lac, ET, IL-6 and TNF-α between the two groups before treatment (P> 0.05) (P <0.01). However, the decrease of DAO, D-Lac, ET, IL-6 and TNF-α in the observation group was significantly better than that in the control group (P <0.05). The effective rate of clinical treatment in the observation group was 89.13% (41/46), which was significantly higher than that in the control group (71.74%, 33/46) (P <0.05). [Conclusion] Jinshuangqi adjuvant treatment of liver cirrhosis SBP can protect the intestinal mucosa, inhibit the inflammatory response, the clinical curative effect is significant, worthy of clinical promotion and use.